Data Sheet (Cat.No.T4337)

TargetMol

PCI 29732

Chemical Properties



CAS No. : 330786-25-9

Formula: C22H21N5O

Molecular Weight: 371.43

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.
Targets(IC50)	BCRP,BTK
In vitro	PCI 29732(compound 1) has a 8.2 nM potency against Btk in a FRET based biochemical enzymology assay. PCI 29732 shows only modest inhibitory activity against Itk, another Tec family kinase, probably due to the difference at the 'gatekeeper" residue. In human CD20+ B cells stimulated at the BCR, PCI-29732 blocked the transcriptional up-regulation of a panel of B-cell activation genes that occurs within 6 h of stimulation. Pulse exposure to the reversible inhibitor PCI-29732 did not result in BCR inhibition.

Solubility Information

Solubility	DMSO: 55 mg/mL (148.08 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.6923 mL	13.4615 mL	26.923 mL
5 mM	0.5385 mL	2.6923 mL	5.3846 mL
10 mM	0.2692 mL	1.3461 mL	2.6923 mL
50 mM	0.0538 mL	0.2692 mL	0.5385 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Pan Z, etal. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem. 2007 Jan;2 (1):58-61.

Honigberg LA, etal. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80.

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481